ALISO VIEJO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., (NASDAQ:RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced today that it intends to offer and sell, subject to market and other conditions, $100 million of shares of its common stock in an underwritten public offering. In addition, RxSight expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering on the same terms and conditions. RxSight intends to use the net proceeds from the offering for continued commercial and marketing expansion, including international expansion, funding of product development, research and clinical development, and for working capital and general corporate purposes. All of the shares are being offered by RxSight. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. BofA Securities is acting as lead bookrunning manager of the offering and as representative of the underwriters.  J.P. Morgan is also acting as bookrunning manager and BTIG is acting as a co-manager of the offering. An automatic shelf registration statement on Form S-3 relating to the common stock offered in the public offering described above was filed with the Securities and Exchange Commission (the "SEC") on May 8, 2024, which became automatically effective upon filing. The proposed offering is being made only by means of a prospectus supplement and accompanying prospectus ...